Patient-reported outcomes and the evolution of adverse event reporting in oncology.
about
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trialsHigh-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trialHarnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial.Evaluating harm associated with anti-malarial drugs: a survey of methods used by clinical researchers to elicit, assess and record participant-reported adverse events and related data.Preliminary Development and Evaluation of an Algorithm to Identify Breast Cancer Chemotherapy Toxicities Using Electronic Medical Records and Administrative Data.Population Analysis of Adverse Events in Different Age Groups Using Big Clinical Trials DataQuantitative tool to evaluate the somatic burden due to chemotherapy-induced adverse events: the somatic burden score.Incidence of adverse events in an integrated US healthcare system: a retrospective observational study of 82,784 surgical hospitalizations.Management of gastrointestinal symptoms in advanced cancer patients: the rapid learning cancer clinic model.Review of a study of duloxetine for painful chemotherapy-induced peripheral neuropathy.Evaluating and reporting dysphagia in trials of chemoirradiation for head-and-neck cancer.Efficacy of transcatheter arterial chemoembolization for liver metastases arising from pancreatic cancer.Testicular cancer survivorship: research strategies and recommendations.Palliative oncology: identity, progress, and the path aheadDevelopment of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinomaAutomated monitoring of symptoms during ambulatory chemotherapy and oncology providers' use of the information: a randomized controlled clinical trial.Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).Improving patient safety via automated laboratory-based adverse event grading.Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer.Predicting outcomes in radiation oncology--multifactorial decision support systemsUse and misuse of common terminology criteria for adverse events in cancer clinical trials.Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).Chemotherapy interruptions in relation to symptom severity in advanced breast cancerValidation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).Concordance between patient reports of cancer-related symptoms and medical records documentationPatient-Reported Outcomes vs. Clinician Symptom Reporting During Chemoradiation for Rectal Cancer.Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.Patient engagement as an emerging challenge for healthcare services: mapping the literatureReliability of adverse symptom event reporting by clinicians.Qualitative Development and Content Validity of the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome Instrument.Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)Using patient-reported outcome measures for improved decision-making in patients with gastrointestinal cancer - the last clinical frontier in surgical oncology?Self-perceptions of age among 292 chemotherapy-treated cancer patients: Exploring associations with symptoms and survival.Radiotherapy for the management of locally advanced squamous cell carcinoma of the head and neck.Automated summaries of serious adverse events in the hepatitis C antiviral long-term treatment against cirrhosis trial.Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges.Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice.Electronic toxicity monitoring and patient-reported outcomes.
P2860
Q26822790-EED2D4B0-A4F5-4344-8C7B-3D25ACD4B6D9Q28545827-8B94D099-A0AF-4319-B9E9-3156338E157EQ30620556-D739840A-1D94-41CF-819E-295804E89026Q30667272-704638A5-6DFD-4044-A117-2FC89EA662B2Q30845285-7C2FE6D8-A60A-4980-AA1F-2A919116BDA9Q31137297-D310819F-1E5B-404C-9EF8-737BFBD992F7Q33416289-2E4EA7CE-D454-48C6-91F2-88C295847612Q33749713-DF03F9C3-50C8-48CB-BABA-F9498710A6AAQ33854239-6894E2AE-4AF7-47DD-96F5-8297D7937710Q33886065-04D8CB00-9BEC-4C92-B782-245C131EDE94Q33886464-EDBE5A52-A2CA-4C43-B695-041825D977D8Q33889370-6A0DA40C-12BA-4977-970E-A6F8891C33F8Q34039684-18D3B19E-301C-48D6-B641-A0EE273A74FAQ34277183-1ACB4FCF-71AE-461A-A068-418ECB7B881BQ34354355-ACEF0292-6CBC-4250-8A2B-24576AAFDEB2Q34367737-5F0A6C95-B792-45FB-8961-FABE966F5A57Q34507381-0C3163A3-FAA2-4FB1-979D-521C1F36FFF9Q34915739-229952A2-2E8B-443C-B6AC-472D94762236Q35000584-F6EF0E3D-F307-4A95-8902-9E762FC2F4A5Q35619111-55019EC9-3EAA-4FC1-8C86-F699E15BF40CQ35749286-D04E288F-E01E-4E0E-9D37-290D42D7A7B0Q36014711-C5B7D1EE-E6E4-4075-9A95-33A902541C04Q36067717-6CEFC7D7-E753-49DB-AB1F-0EF41376C3D7Q36080860-5AAEFEE6-7AC2-4C10-AE7C-A55AC0FA3F3BQ36093736-33A03381-6552-479A-BB8F-17723F132DF4Q36147112-45933D9F-5DBE-4834-AA3D-24663BCB2151Q36205212-CC3F98BC-A0E5-4BD4-9B4C-3CF40912A2BEQ36206899-7BE8679E-5A99-4133-A6B4-29B459B65423Q36243104-3FCD438D-EEA8-45C8-B126-1BEF156674DEQ36418040-3512AAF6-7957-4362-93BB-220C9CF79D71Q36787723-B66AEA94-56FA-41B2-A7D6-B175913A09B6Q36854048-C6E1702E-6C09-4A63-A9B9-46BE59FBB599Q36872264-DF45DCA3-6E21-450A-831F-F6636224079DQ36927798-28509767-12ED-4407-AD0B-6EE5E74CBF41Q36938460-DA4866F9-C16F-483A-83B6-5BC89818F579Q37093034-28475FCB-6DEB-458A-BB8F-21259A3CFC35Q37122538-4A8C04BF-0DAE-45AD-9051-375CECE1F878Q37217253-A61E6F72-CAE6-421B-9957-0F71D77F19E6Q37270640-D0EEE0D0-409B-45A9-8FA6-3C9F9116555EQ37373649-6F0C2C9E-31F7-4E9D-8FEA-7EDEC0C17F6D
P2860
Patient-reported outcomes and the evolution of adverse event reporting in oncology.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Patient-reported outcomes and the evolution of adverse event reporting in oncology.
@en
type
label
Patient-reported outcomes and the evolution of adverse event reporting in oncology.
@en
prefLabel
Patient-reported outcomes and the evolution of adverse event reporting in oncology.
@en
P2093
P356
P1476
Patient-reported outcomes and the evolution of adverse event reporting in oncology.
@en
P2093
A Dimitrios Colevas
Andy Trotti
Ann Setser
P304
P356
10.1200/JCO.2007.12.4784
P407
P50
P577
2007-11-01T00:00:00Z